The S-4 confirms Fulcrum is being acquired for its net cash and public listing, not its pipeline. The ~$270M special dividend provides a near-term cash return, but the 5% pro forma ownership stake means existing Fulcrum shareholders will have negligible ongoing exposure to Slate's migraine programs. Monitor the stockholder vote and any potential competing bids; the low valuation of Fulcrum ($31.3M) relative to its ~$318.8M cash position suggests the market may have already priced in a liquidation discount.
How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+20- T+0 · Sep 2 $3.85entry
- T+1 · 3mo ago −0.26%α −1.31% · $3.84
- T+5 · 2mo ago −1.30%α −0.34% · $3.80
- T+20 · 7w ago −3.90%α −3.57% · $3.70
- T+52 · todayOpen
- T+60 · in 10d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Fulcrum Therapeutics (FULC) filed an S-4 registration statement for a reverse merger with privately-held Slate Medicines. Under the agreement, pre-merger Slate stockholders (excluding concurrent investors) will own ~55.9% of the combined company, new investors in a concurrent $245M investment will own ~39.1%, and pre-merger Fulcrum stockholders will own only ~5.0% on a fully diluted basis. Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270M, but their equity stake in the combined entity is minimal, making this effectively a sale of Fulcrum's public shell and net cash to Slate.
Key Facts
- Pre-merger Fulcrum stockholders will own only ~5.0% of the combined company on a fully diluted basis.
- Pre-merger Slate stockholders (excluding investors) will own ~55.9%, and new investors in a $245M concurrent investment will own ~39.1%.
- Fulcrum stockholders will receive a special pre-closing cash dividend of approximately $270 million.
- Fulcrum's valuation is assumed at $31.3M, subject to downward adjustment if net cash at closing is less than $20.3M.
- Fulcrum has discontinued its pociredir program and reduced its workforce by ~85% to nine employees.
- The combined company will be renamed Slate Medicines, Inc. and trade under the symbol SLTE.
- Slate's lead candidate, SLTE-1009, is a clinical-stage bispecific antibody targeting PACAP/VIP for migraine prevention.
- Fulcrum's board recommends voting FOR all proposals, including the stock issuance and reverse stock split.
Financial Impact
Fulcrum stockholders' ownership diluted to ~5% of combined entity; special dividend of ~$270M to be distributed to pre-merger Fulcrum holders.
Risk Factors
- Stockholder approval may not be obtained, causing the merger to fail and Fulcrum to pursue a potentially less favorable liquidation.
- The exchange ratio is fixed and does not adjust for Fulcrum's stock price, creating value uncertainty for Slate stockholders.
- Slate's lead candidate SLTE-1009 is early-stage and unproven in humans, with no anti-PACAP therapy ever approved.
- The combined company will need substantial additional capital beyond the $245M concurrent investment to fund development.
- Fulcrum's remaining nine employees may be insufficient to manage the merger process and regulatory obligations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 2 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-4 Filing (Primary) | 0001193125-26-379106 |
| Document: d127837dex1014.htm | 0001193125-26-379106 |
Track record
23 reports on FULC
5 of 6 bullish or bearish reports moved the stock their way by T+1. Best: +7.71% at T+60 after the Jul 15, 2026 report. 6 of 6 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $3.72 Now $3.71 −0.27% settles Nov 18
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $3.73 Now $3.71 −0.40% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $3.77 Now $3.71 −1.59% settles Nov 17
- Nov 12, 20264d ago 425 Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 12, 20264d ago 8-K Neutral 3/10 Entry $3.77 to $3.71 Now $3.71 −1.59% ▼ −1.59% +0.32% vs SPY
- Nov 5, 202612d ago EFFECT Neutral 4/10 Entry $3.68 to $3.70 Now $3.71 +0.82% ▲ +0.54% +0.23% vs SPY
- Nov 3, 202613d ago S-4/A Neutral 5/10 Entry $3.74 to $3.77 Now $3.71 −0.80% ▲ +0.80% −0.85% vs SPY
- Oct 28, 202619d ago SC 13G/A Neutral 2/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
- Oct 27, 202620d ago SC 13G/A Neutral 3/10 Entry $3.75 to $3.77 Now $3.71 −1.07% ▲ +0.53% +0.92% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers